Brief: Apyx Medical Corporation Announces FDA 510(K) Submission For The Use Of Renuvion® In Dermal Resurfacing Procedures
01/06/2021 12:43
June 1 (Reuters) - Apyx Medical Corp APYX.O :
* APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION
FOR THE
USE OF RENUVION® IN DERMAL RESURFACING PROCEDURES
Source text for Eikon: ID:nBw757Nrya
Further company coverage: APYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apyx Medical
See all newsBrief: Apyx Medical - Appoints Stavros Vizirgianakis As Executive Chairman Effective June 11, 2026
Brief: Apyx Medical Corporation Receives Expanded FDA 510(K) Clearance Adding Power Liposuction Capability To AYON Body Contouring System™
Apyx Medical Q1 revenue beats estimates, outlook raised
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength